[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023003995A - Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl. - Google Patents

Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.

Info

Publication number
MX2023003995A
MX2023003995A MX2023003995A MX2023003995A MX2023003995A MX 2023003995 A MX2023003995 A MX 2023003995A MX 2023003995 A MX2023003995 A MX 2023003995A MX 2023003995 A MX2023003995 A MX 2023003995A MX 2023003995 A MX2023003995 A MX 2023003995A
Authority
MX
Mexico
Prior art keywords
bcr
inhibition
tyrosine kinases
abl tyrosine
compounds
Prior art date
Application number
MX2023003995A
Other languages
English (en)
Inventor
Joseph P Lyssikatos
Li Ren
Samuel Kintz
Original Assignee
Enliven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enliven Inc filed Critical Enliven Inc
Publication of MX2023003995A publication Critical patent/MX2023003995A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El presente documento se refiere a compuestos y composiciones para la inhibición de tirosina cinasas Bcr-Abl, métodos para preparar dichos compuestos y composiciones, y su uso en el tratamiento de varios tipos de cáncer, como la leucemia mieloide crónica (LMC).
MX2023003995A 2020-10-05 2021-10-04 Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl. MX2023003995A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087763P 2020-10-05 2020-10-05
US202163224236P 2021-07-21 2021-07-21
PCT/US2021/071695 WO2022076975A1 (en) 2020-10-05 2021-10-04 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases

Publications (1)

Publication Number Publication Date
MX2023003995A true MX2023003995A (es) 2023-06-12

Family

ID=81125530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003995A MX2023003995A (es) 2020-10-05 2021-10-04 Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.

Country Status (10)

Country Link
US (3) US11767321B2 (es)
EP (1) EP4225742A4 (es)
JP (2) JP7588224B2 (es)
KR (1) KR20230104781A (es)
CN (1) CN119019388A (es)
AU (1) AU2021358123A1 (es)
CA (1) CA3196620A1 (es)
IL (1) IL301739A (es)
MX (1) MX2023003995A (es)
WO (1) WO2022076975A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076975A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2023081637A1 (en) 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6253076B1 (en) 1999-02-25 2001-06-26 Ericsson Inc. Manufacturing method for wireless communications devices employing potentially different versions of integrated circuits
EP1165076A4 (en) 1999-03-10 2002-05-15 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS GONADOLIBERINE'S ANTAGONISTS
EP1161431A4 (en) 1999-03-10 2002-04-24 Merck & Co Inc 6-AZAINDOLE COMPOUNDS FOR USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS
WO2001032658A1 (fr) 1999-11-02 2001-05-10 Ajinomoto Co., Inc. Compose de polyazanaphtalene et utilisation medicinale dudit compose
JP2003519232A (ja) 2000-01-07 2003-06-17 ウニフェルジテーレ・インステリング・アントウェルペン プリン誘導体、その製造法およびその使用
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
WO2001072708A2 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
EP1268432A1 (en) 2000-03-24 2003-01-02 Millenium Pharmaceuticals, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
US20030186972A1 (en) 2001-03-26 2003-10-02 Millennium Pharmaceuticals, Inc. Isoquinolone inhibitors of factor Xa
US20050130977A1 (en) 2002-04-08 2005-06-16 Lindsley Craig W. Inhibitors of akt activity
NZ536794A (en) 2002-06-06 2007-04-27 Eisai Co Ltd Condensed imidazole derivatives
AU2003254657A1 (en) 2002-07-25 2004-02-16 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20060094722A1 (en) 2002-09-26 2006-05-04 Eisai Co., Ltd. Combination drug
JP2007501618A (ja) 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
BRPI0413695A (pt) 2003-08-22 2006-10-24 Avanir Pharmaceuticals derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas
WO2005053695A1 (ja) 2003-12-04 2005-06-16 Eisai Co., Ltd. 多発性硬化症予防剤または治療剤
EP1709045A1 (en) 2003-12-09 2006-10-11 Vertex Pharmaceuticals Incorporated Naphthyridine derivatives and their use as modulators of muscarinic receptors
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CA2647100A1 (en) 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
AU2007254491A1 (en) 2006-05-15 2007-11-29 Irm Llc Compositions and methods for FGF receptor kinases inhibitors
CN101790527A (zh) 2006-07-20 2010-07-28 凯利普西斯公司 Rho激酶的苯并噻吩抑制剂
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP5639762B2 (ja) 2006-12-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド ウイルス阻害剤
MX2010001650A (es) 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
EP2244709A4 (en) 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
ES2570429T3 (es) 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
FR2941948B1 (fr) 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
AU2010266570A1 (en) 2009-06-30 2012-01-19 Siga Technologies, Inc. Treatment and prevention of Dengue virus infections
DE102009033208A1 (de) 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
AU2010307006B2 (en) 2009-10-13 2016-08-11 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
EP3001903B1 (en) 2009-12-21 2017-10-25 Samumed, LLC 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN103282034A (zh) 2010-11-18 2013-09-04 利亘制药公司 造血生长因子模拟物的用途
EA026115B1 (ru) 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
EP2669270B1 (en) 2011-01-28 2018-01-03 Sato Pharmaceutical Co., Ltd. Indole-related compounds as urat1 inhibitors
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
EP2570125A1 (en) 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
DE102011121022A1 (de) 2011-12-13 2013-06-13 Merck Patent Gmbh Organische Sensibilisatoren für Up- Conversion
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3000492B1 (fr) * 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
EP2818472A1 (en) 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3140274A1 (en) 2014-05-09 2017-03-15 Sloan-kettering Institute For Cancer Research Naphthaquinone methyltransferase inhibitors and uses thereof
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
US20150376219A1 (en) 2014-06-30 2015-12-31 Minghong Zhong Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods
EP3169678A1 (en) 2014-07-17 2017-05-24 Merck Patent GmbH Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
WO2016014674A1 (en) 2014-07-22 2016-01-28 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
WO2016144351A1 (en) 2015-03-11 2016-09-15 E. I. Du Pont De Nemours And Company Heterocycle-substituted bicyclic azole pesticides
WO2016144706A2 (en) 2015-03-11 2016-09-15 Pharmakea, Inc. Autotaxin inhibitor compounds and uses thereof
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
WO2017049165A1 (en) 2015-09-18 2017-03-23 The Scripps Research Institute Rna-focused small molecules for inhibiting rna toxicity in myotonic dystrophy
DK3377488T3 (da) 2015-11-19 2022-10-03 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
JP6577051B2 (ja) 2015-12-01 2019-09-18 日本農薬株式会社 ３ｈ‐ピロロピリジン化合物若しくはそのｎ‐オキサイド、又はそれらの塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
CA3020778A1 (en) 2016-04-15 2017-10-19 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
LT3442535T (lt) 2016-04-15 2022-10-25 Cancer Research Technology Limited Heterocikliniai junginiai kaip ret kinazės inhibitoriai
JP7039802B2 (ja) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
ES2969536T3 (es) 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
CN110573501B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN109721620B (zh) 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
WO2019126082A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
CA3093527A1 (en) 2018-03-13 2019-09-19 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
EP3774709A4 (en) 2018-03-28 2021-12-22 Peloton Therapeutics, Inc. METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM USING HIF-2-ALPHA INHIBITORS
WO2020021024A1 (en) 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN117186092A (zh) 2018-11-07 2023-12-08 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
WO2020103896A1 (en) 2018-11-22 2020-05-28 Beigene, Ltd. Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
PE20220166A1 (es) 2019-03-05 2022-01-28 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad
PE20221003A1 (es) 2019-06-12 2022-06-15 Tmem16A Ltd Compuestos para tratar enfermedad respiratoria
JP2022540336A (ja) 2019-07-09 2022-09-15 アイカジェン リミテッド ライアビリティ カンパニー Ｂｃａｔモジュレーション
WO2021013083A1 (en) 2019-07-17 2021-01-28 Beigene, Ltd. Tricyclic compounds as hpk1 inhibitor and the use thereof
CN112341477B (zh) 2019-08-09 2023-07-21 四川科伦博泰生物医药股份有限公司 含有并环基团的咪唑并嘧啶类化合物、其制备方法及用途
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022076975A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases

Also Published As

Publication number Publication date
EP4225742A1 (en) 2023-08-16
US11807638B2 (en) 2023-11-07
AU2021358123A9 (en) 2024-07-25
US20230382907A1 (en) 2023-11-30
AU2021358123A1 (en) 2023-06-08
IL301739A (en) 2023-05-01
WO2022076975A1 (en) 2022-04-14
US20230130724A1 (en) 2023-04-27
CN119019388A (zh) 2024-11-26
JP7588224B2 (ja) 2024-11-21
US20230065635A1 (en) 2023-03-02
US11767321B2 (en) 2023-09-26
JP2024153884A (ja) 2024-10-29
CA3196620A1 (en) 2022-04-14
JP2023546352A (ja) 2023-11-02
EP4225742A4 (en) 2024-11-06
KR20230104781A (ko) 2023-07-10

Similar Documents

Publication Publication Date Title
MX2023003996A (es) Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl.
MX2021003517A (es) Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
AR067505A1 (es) Derivados de pirimidinil-piridazinona
MX2018007267A (es) Compuestos utiles como inhibidores de cinasa.
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
PH12019502138A1 (en) Compounds and compositions for treating hematological disorders
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12020500343B1 (en) Pyruvate kinase activators for use in treating blood disorders
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
NZ722326A (en) Tricyclic compounds as anticancer agents
MX2023003995A (es) Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.
MX2009013077A (es) Derivados dde benzoxazolona.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
EP4338802A3 (en) Tyk2 inhibitors, uses, and methods for production thereof
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2021002998A (es) Compuestos de triazolo-pirimidina y usos de los mismos.
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
DOP2011000129A (es) 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.